Pituitary tumor angiogenesis

Endocrinologist

Volumn 11, Issue 6, 2001, Pages 465-469

  Turner, Helen E ^a  

^a RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FUMAGILLOL CHLOROACETYLCARBAMATE; GELATINASE B; LEUKEMIA INHIBITORY FACTOR; PROLACTIN; VASCULOTROPIN;

ACROMEGALY; ANGIOGENESIS; CUSHING DISEASE; HORMONAL REGULATION; HUMAN; HYPOPHYSIS TUMOR; PROLACTINOMA; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

EID: 0035205312     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019616-200111000-00007     Document Type: Review

References (42)

1. What is the evidence that tumours are angiogenesis dependent?
2. Tumour angiogenesis: A new significant and independent prognostic indicator in early stage breast carcinoma
3. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
4. Ultrastructural changes in the capillary bed of human pituitary tumours
5. Vasculature in nontumerous hypophyses, pituitary adenomas and carcinomas: A quantitative morphologic study
6. Angiogenesis in pituitary adenomas and the normal pituitary gland
7. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer
8. Angiogenesis as a marker of preneoplastic lesions of the human breast
9. Pituitary, adrenal and thyroid incidentalomas
10. Microvasculature of human micro- and macroprolactinomas. A morphological study
11. An immunohistochemical study of tumour vessels in metastatic liver cancers and the surrounding liver tissue
12. Functional grafts of anterior pituitary gland
13. The primary angiographic findings in pituitary adenomas
14. Sequential MR enhancement pattern in normal pituitary gland and pituitary adenoma
15. Microadenomas of the human pituitary and their vascularisation
16. Morphological evidence for the presence of arteries in human prolactinomas
17. Formation of a direct arterial blood supply to the anterior pituitary gland following complete or partial interruption of the hypophyseal portal vessels
18. Inhibition of estrogen-induced anterior pituitary enlargement and arteriogenesis by bromocriptine in Fischer 344 rats
19. Immunocytochemical investigations on the vascularisation of pituitary adenomas
20. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker
21. Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas-relationship to tumour behaviour
22. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
23. The biology of vascular endothelial growth factor
24. Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumours may mediate oestrogen-initiated tumour angiogenesis
25. Pattern and localisation of expression of vascular endothelial growth factor and its receptor flt1 in the ovine pituitary gland: Expression is independent of hypothalamic control
26. Immunolocalisation of vascular endothelial growth factor in the GH3 cell line
27. Pituitary adenylate cyclase-activating polypeptide, interleukin-6 and glucocorticoids regulate the release of vascular endothelial growth factor in pituitary folliculostellate cells
28. Expression of vascular endothelial growth factor in human brain tumours
29. Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas
30. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
31. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
32. Pituitary follicular cells secrete an inhibitor of aortic endothelial cell growth: Identification as leukemia inhibitory factor
33. Biological and immunological characterization of cleaved and 16K forms of rat prolactin
34. A 14-kilodalton prolactinlike fragment is secreted by the hypothalamo-neurohypophyseal system of the rat
35. A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells
36. Human and murine pituitary expression of leukaemia inhibitory factor
37. Inhibitory effect of TNP-470, a new anti-angiogenic agent, on the estrogen induced rat pituitary tumors
38. Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent
39. High levels of matrix metalloproteinases regulate proliferation and hormone secretion in pituitary cells
40. Role of matrix metalloproteinase 9 in pituitary tumours
41. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas
42. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis